IN Capital strives to become the leading healthcare investment firm in China
Zhang Caixia

Caixia joined IN CAPITAL in 2015. Prior to joining IN CAPITAL, Caixia worked in a CRO company and was responsible for the evaluation of innovative drugs and the its drug formation.

Caixia holds a bachelor's degree of pharmacy from Zhejiang University and a PhD of microbiology and biochemical pharmacy from Public Union Medical College. Caixia has basic scientific research experience for 5 years, and her study was focused on molecular mechanism of tumor and screening anti-tumor drugs include small molecule targeting drugs, antibody drugs and targeted combined therapy. She has published 3 SCI as the first author. 

Copyright © In Capital 2019